Manejo de la insuficiencia cardiaca

Disease Management Programs in Heart Failure: One Step Beyond Pharmacology Programas de manejo en la insuficiencia cardiaca: un paso más allá de la farmacologı́a

Despite pharmacological advances, both mortality and the incidence of hospital admissions are high for heart failure. As with many other chronic diseases, the findings of clinical trials are difficult to implement due to lack of adherence to treatment, frequent comorbidities not considered in clinical trials, and health systems’ typical focus on acute diseases. Public health systems usually pay...

Pulmonary Congestion in Acute Heart Failure: From Hemodynamics to Lung Injury and Barrier Dysfunction Congestión pulmonar en la insuficiencia cardiaca aguda: de la hemodinámica a la lesión pulmonar y la disfunción de la barrera alveolocapilar

Acute heart failure (AHF) has been defined as new-onset or worsening heart failure (HF) signs and symptoms requiring urgent therapy. AHF is a leading cause of morbidity and mortality. Despite the considerable variation of clinical profiles and the substantial heterogeneity of underlying causes, the vast majority of patients with AHF present with symptoms and signs of pulmonary and systemic cong...

Levosimendan: Nueva estrategia en el manejo de la falla cardíaca

[Is digitalis currently useful for heart failure treatment?].

Después del estudio DIG publicado en 19971 se ha observado un franco declive en el uso de la digital para el tratamiento de la insuficiencia cardiaca; más aún cuando han emergido nuevos medicamentos que han demostrado su utilidad en estos pacientes, especialmente porque reducen significativamente la mortalidad, y es por ello que viene a la mente que un fármaco tan antiguo como la digital está r...

Red Cell Distribution Width Measurement: What Role Does It Have in Heart Failure? Determinación del ancho de distribución eritrocitaria. Utilidad en la insuficiencia cardiaca

Over the past decade, there has been a literal explosion of studies examining various prognostic biomarkers in patients with heart failure. Some of these biomarkers—such as the natriuretic peptides—directly reflect pathophysiologic processes in the diagnosis, while the prognostic links for other ‘‘heart failure biomarkers’’ remain less well-defined. In the article published in Revista Española ...